Stifel analyst Alex Thompson raised the firm’s price target on Ascendis Pharma (ASND) to $256 from $254 and keeps a Buy rating on the shares. The firm “refreshed diligence” on many companies within its biotechnology coverage universe and made a number of model, estimate and price target changes in a 2026 look ahead note for the group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma Grants Employee Warrants to Strengthen Market Position
- Positive Outlook for Ascendis Pharma: Buy Rating Despite PDUFA Delay
- Ascendis Pharma Faces FDA Delay for TransCon CNP Approval
- Positive Outlook on Ascendis Pharma Despite PDUFA Date Extension for TransCon CNP
- Ascendis Pharma annouces FDA extension for TransCon CN